Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
Silvia Novello(University of Turin), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Anna K. Nowak(The University of Western Australia), David Planchard(Université Paris-Saclay), Jakob B. Sørensen(University of Copenhagen), Federica Grosso(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Sanjay Popat(Royal Marsden NHS Foundation Trust), Brett Hughes(Royal Brisbane and Women's Hospital), Giovanni Luca Ceresoli(Humanitas Gavazzeni), Julien Mazières(Université Toulouse III - Paul Sabatier), Nassim Morsli(Boehringer Ingelheim (France)), Martin Reck(German Center for Lung Research), Laurent Greillier(Aix-Marseille Université), Mark A. Socinski(Florida Hospital Cancer Institute), Ute von Wangenheim(Boehringer Ingelheim (Germany)), Nick Pavlakis(The University of Sydney), Thomas John(Austin Hospital), José Barrueco(Georgetown University), Nicola Steele(Cancer Research UK Scotland Institute), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k